Download Free Medical Radiotherapy and Chemotherapy in Gynaecology PowerPoint Presentation

Radiotherapy and Chemotherapy in Gynaecology PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Radiotherapy and Chemotherapy in Gynaecology”.

This medical PowerPoint presentation is about radiotherapy and chemotherapy, two common treatments used in gynecological cancer care. Both of these treatments can be used alone or in combination with other treatments, such as surgery.

Radiotherapy involves the use of high-energy radiation to kill cancer cells or shrink tumors. It is typically administered from an external machine, but can also be given internally, using radioactive implants or injections. Radiotherapy can be used as the primary treatment for certain gynecological cancers, or as an adjuvant treatment following surgery to destroy any remaining cancer cells.

Chemotherapy, on the other hand, uses drugs to destroy cancer cells. These drugs can be administered orally or intravenously, and are designed to target rapidly dividing cells, including cancer cells. Chemotherapy can be used alone or in combination with other treatments, such as surgery and radiation therapy. It is often used to treat more advanced or aggressive forms of gynecological cancer, or in cases where the cancer has spread to other parts of the body.

In gynecological cancer care, radiotherapy and chemotherapy can be used in combination to improve treatment outcomes. This is known as chemoradiotherapy. The goal of this approach is to increase the effectiveness of radiation therapy by making cancer cells more sensitive to the radiation.

Overall, the use of radiotherapy and chemotherapy in gynecological cancer care will depend on the type and stage of the cancer, as well as the individual patients health status and treatment goals. Your healthcare team will work with you to determine the best treatment plan for your specific situation.

Tags : Radiotherapy, Chemotherapy, Gynaecology, gynecological cancer care, Gynaecology, Gynaecology PowerPoint presentation, Gynecologic Oncology, Gynecologic Oncology PowerPoint presentation

Published on : May 29, 2023 | Views : 1110 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

GYNAECOLOGYRADIOTHERAPY AND CHEMOTHERAPY IN GYNAECOLOGY
Slide 2-

PRINCIPLES OF RADIATION THERAPY Following the discovery of x-ray the biological effect of ionizing radiation (IR) has been used either alone or in conjunction with other modalities to treat variety of condition being or malignant RT can be directed by external beam therapy ,internal placement of radio nucleotide sources, termed brachytherapy or by instillation of radio nucleotide
Slide 3-

THE ROLE OF RADIATION THERAPY IN THE MANAGEMENT OF GYNECOLOGICAL CANCERS Intent site Curative cx,vulva,vagina Adjunvctive to surgery cx ,vulva,vagina, uterus Palliative metastasis causing symptoms ,bleeding ,pain obstruction ,spinal compression, brain metastasis As adjuvant treatment in the post operative setting if there is a high probability of regional recurrence . for uterus occasionally as primary modality for inoperable tumors For epithelial ovarian tumor ,the indication for RT as minimal limited role for external beam therapy in germ cell tumor and gestation trophoblastic neoplasia
Slide 4-

RADIOTHERAPY EXTERNAL RADIATION THERAPY Indicated when an area to be irradiated is large ,e.g cx cancer and the draining nodes The basic tent of radiation therapy is to maximize the tumor dose while minimizing the the damage to the surrounding normal tissues ,the area determined by means of CT MRI
Slide 5-

BRACHYTHERAPY Radiation implants ,means treatment at a short distance during this therapy sealed or unsealed radioisotopes are inserted or instilled in to the cancer or its immediate vicinity Indicated only when the cancer volume is small ,less than 3-4cm in greatest dimension . BT is typically practiced after external radiation therapy has decreased the tumor size Intra cavitory, interstitial, intra peritoneal brachytherapy: During intra cavitory BT ,the applicators holding the sealed sources, such as cesium are inserted in to a body cavity such as the uterus, interstitial BT requires the placement of catheters or needles directly in to the cancer and surrounding tissues. The typical sources used in interstitial brachytherapy is irridum unsealed sources, such as phosphorus and gold are available as solutions for instillation in to peritoneal cavities
Slide 6-

NORMAL TISSUE RESPONSE TO IONIZING RADIAATION In general radiation therapy is less well tolerated when: 1-the volume of tissues irradiated is larger 2-IR dose is high 3- the dose per fraction is larger 4-the patient age is advanced 5-others can exacerbated the radiation damage to normal tissue these include previous surgery 6-Concurrent chemotherapy 7-Infection 8-Diabetes mellitus 9-HT 10- inflamatory condition (crohn disease)
Slide 7-

Tissue with rapid proliferation rate such as epithelium of the small intestine or oral cavity are irradiated the onset of acute clinical S/S with in few days or weeks This in contrast with tissues such as muscular renal ,neural tissues, which have low proliferative rates and may not display signs of radiation damage for months to years after treatment The concepts of tolerance doses for normal tissues was developed as guide to avoid serious complication in clinical radiation oncology practice
Slide 8-

1-epithelium and parenchyma Atrophy is the most consistent sequel (include lining epithelium skin GIT……..) necrosis ,ulceration ,capillary the most sensitive vessels ,rupture wall ,large arteries (atheroma-like calcification) 2-skin erythema dry desqumation, necrosis ,hyper and hypopigmentation can be seen ,the skin remains atrophied, thin and dry 3-vagina commonly leads to acute vaginal mucositis mucosal ulceration is rare delayed reaction ,vaginal shortening ,atrophic vaginitis ,formation of synechiae or telangictasia ,these avoided ,by use the dilators vaginal intercourse resumed following treatment Rectovaginal fistula can develop after IR sexual dysfunction
Slide 9-

4-ovary and pregnancy outcomes It s effect depend on age and dose of IR above 40 years sterility Among female childhood cancer survivors who received abd irradiation ,higher spontaous abortion ,lower first born weight 5-bladder acute cystitis 2-3 weeks of start treatment frequency ,pain develop commonly hematuria is rare Major chronic complications bladder contracture , haematuria 6- small bowel vulnerable to IR acute early damage acute malabsorption syndrome (nusea ,vomiting,diarrhea,pain) later chronic nature of radiation induced enteritis
Slide 10-

7-kidney acute radiation nephropathy typically 6-12 month after IR expose ,chronic nephropathy 8-Radiation induced carcinogenesis In general ,those receiving higher IRdose and those expose at an earlier age have increased risks for 2nd malignancies, and susceptibility of specific to types to radiatin – induced carcinogenesis High breast BM Moderate ovary bladder Low cx uterus rectum
Slide 11-

PRINCIPLES OF CHEMOTHERAPY INTRODUCTION Each tumor type has its own characteristics ,which explains why the same chemotherapy regimen is not equally effective for the whole spectrum of gynaecology cancers THE CELL CYCLE G0 resting phase G1 protein synthesis RNA synthesis ,DNA repair S new DNA synthesis G2premitotic phase phase twice DNA, contact as they prepare for division M actual mitosis chromosomal division
Slide 12-

CLINICAL SETTING CLINICAL USE OF CHEMOTHERPY Chemotherapy may be used in different ways INDUCTION CHEMOTHERAPY is define as primary for patients with an advanced malignancy when no feasible alternative treatment exists ADJUVANT CHEMOTHERAPY describes systemic treatment after a primary tumor has been controlled but risk of recurrence remains high NEOADJUVANT CHEMOTHERAPY Refers to drug treatment directed at an advanced cancer to decrease preoperatively the extent or morbidity of a subsequent surgical resection SALVAGE CHEMOTHERAPY applied to recurrent disease or to a tumor that is refreactory to initial treatment
Slide 13-

Combination therapy In principle combination of chemotherapy provides maximum cell kill with minimal or tolerable adverse patient side effect Drugs are selected based on their proven efficacy as single agents, different mechanisms of action ,and minimally over lapping toxicities Multiple drugs with different mechanism of action tends to minimize the emergence of drug resistance Drugs used in any combination should have clinical data indicating that their effects will be synergistic at least additive evaluating response to chemotherapy
Slide 14-

CLINICAL END POINTS IN EVALUATING RESPONSE TO CHEMOTHERAPY -Partial response a decrease of 50%or more in the product of all measurable lesion lasting for at least one month with out the development of new lesions -Stable disease of less than 50% of an increase of 25%in the product of the diameters of all measurable disease -Progression an increase of 25% or more of measurable lesion as described above or the identification of new lesions -Complete complete resolution of all disease lasting for at least one month
Slide 15-

CHEMOTHERAPUTIC DRUGS In gynecological oncology diverse compounds that have demonstrated activity includes Antimetabolites ,alkalating agents ,anti tumor antibiotic ,plant alkaloids ,hormonal agents ,biologic therapies These drugs may be used as single agent or in combination regimens ATIMETABOLITES Analoge of naturaly occurring substances in the metabolic pathways leading to the synthesis of purines , pyrimidines ,and nuclic acids In most case ,they are S phase specific agents that are most effective in rapidly growing tumors associated with short doubling times and large growth fractions e.g methotrexate tightly binds to dihydrofolate reductas , blocking the reduction of dihydrofolate to active form of folic acid various steps in denovo purine syntheis are halted ,arrest DNA,RNA protein synthesis cause fatal bone marrow toxicity this can be prevented by early administration of folinic acid renal toxicity ,acute cerebral dysfunction ,excreted through the kidney
Slide 16-

ALKYLATING AGENTS Bind to DNA breaks DNA synthesis work at any phase of active replication Cyclophosphamide oral ,iv, toxicity chief role is as part of combination chemotherapy cyclophosphomide is the C of the EMA-CO in GTN treatment or use as s ingle agent salvage therapy for recurrent epithelial ov.cancer
Slide 17-

ANTITUMOR ANTIBIOTICS Derived from microorganism antitumor antibiotics exert their cytotoxic effects by DNA inter calation they cell cycl non specific DACTINOMYCIN This agent is used to treat GTN as a single agent or as a part of combination chemotherapy also known as adriamycinD is A of EMA-CO is a product of the genus ;streptomyces and because anchored in to purine –pyrimidne DNA base pairs resulting in inhibition of DNA synthesis ,excreted through billiary tree give i.v. rout toxicity Bone marrow depression ,nusea vomiting allopacia
Slide 18-

PLANT—DERIVED AGENTS Disturbance of normal assembly ,disassembly and stabilization of intracellular microtubules Taxanes ,vinca alkaloids ,topiosomerase inhibitor TAXANES Paclitaxel cell cycl specific agents maximal activity during the M phase they act to poison ,the mitotic spindle by preventing depolymerization of the microtubules,and inhibition cellular replication Given I.V for recurrent of epithelial tumor ,ca ovary, end ca, ca cx,GTN S.E peripheral neuropathy,neurotoxicity BMD, alopecia ,bradycardia,hypersensitivity reaction
Slide 19-

polymerization by binding to the tubulin ,at different side is of EMA-CO GTN Neurotoxicity is the most common dose limiting toxicity BIOLOGICAL THERAPY Designed to more accurately target specific tumors while avoiding much of the toxicity seen in refered to as immunotherapy or biological response modifer therapy May enhance the chemosensitivity of malignant cell to treatmrnt or may use the body immune system to attack the cancer VACCINES Therapeutic cancer vaccines are designed to induce cellular component of the immune system to recognize and attack tumors Bone toxicity ,GTT toxicity